Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test. The findings of the study will be presented Wednesday, November 10th at the Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia.

9 Nov 2010

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

New approach to treat castration resistant prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

Merrimack receives $2.44 million under QTDP program to support cancer research

Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.

9 Nov 2010

Fabrus, Ambrx commence joint research program for antibody drug conjugates

FABRUS, LLC announces that the Company and San Diego-based Ambrx Inc. have commenced a joint research program to discover antibodies with properties that are optimized for use as antibody drug conjugates.

9 Nov 2010

Vaccinations do not increase risk of RA

Common adult vaccinations are not associated with an increased risk of developing rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present new data relating to Soliris (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held December 4 - 7, 2010 at the Orange County Convention Center in Orlando.

9 Nov 2010

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Amgen today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the following: a pathologic fracture, the need for radiation or surgery to ameliorate bone pathology secondary to tumor growth, or spinal cord compression.

8 Nov 2010

Calypte receives $244,479 tax credit under QTDP program

Calypte Biomedical Corporation, the developer, manufacturer and marketer of the Aware HIV-1/2 OMT (oral fluid) HIV test, announced today that it has been awarded a tax credit of $244,479 under U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

Progenics third quarter net loss increases to $17.1 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2010.

8 Nov 2010

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Santarus, Inc. a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis.

8 Nov 2010

Maternal peanut consumption during pregnancy increases peanut allergy risk in children

Babies born to mothers who eat peanuts during pregnancy appear more prone to peanut allergy, according to research conducted by scientists at Johns Hopkins Children's Center and elsewhere and published online in the Journal of Allergy and Clinical Immunology. The research team was led by Scott Sicherer, M.D., of the Mount Sinai School of Medicine in New York.

8 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project program.

8 Nov 2010

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

An experimental drug for Hodgkin's lymphoma, studied at the University of Alabama at Birmingham, showed beneficial effects in stopping tumor growth with moderate side-effects, according to findings published Thursday in the New England Journal of Medicine.

8 Nov 2010

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Alder Biopharmaceuticals Inc. today announced that data from two clinical studies of its ALD518 investigational antibody therapeutic will be presented at the Annual Meeting of the American College of Rheumatology in Atlanta.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Antibody News and Research

Further Reading

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

New approach to treat castration resistant prostate cancer

SIMPONI injection improves inflammation, structural damage in RA patients

Merrimack receives $2.44 million under QTDP program to support cancer research

Fabrus, Ambrx commence joint research program for antibody drug conjugates

Vaccinations do not increase risk of RA

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Calypte receives $244,479 tax credit under QTDP program

Progenics third quarter net loss increases to $17.1 million

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Maternal peanut consumption during pregnancy increases peanut allergy risk in children

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Antibodies eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News